Original price was: $149.99.$119.99Current price is: $119.99.
Research Studies:
FREE Shipping on
orders over $200
ALL ARTICLES AND PRODUCT INFORMATION PROVIDED ON THIS WEBSITE ARE FOR INFORMATIONAL AND EDUCATIONAL PURPOSES ONLY. The products offered on this website are intended solely for research and laboratory use. These products are not intended for human or animal consumption. They are not medicines or drugs and have not been evaluated or approved by the FDA to diagnose, treat, cure, or prevent any disease or medical condition. Any form of bodily introduction is strictly prohibited by law.
Kisspeptin 10mg is a cutting-edge research peptide recognized for its pivotal role in reproductive hormone regulation. Sourced from premium raw materials and synthesized using advanced methodologies, our Kisspeptin is crafted to deliver high purity and potency—ideal for intensive research applications.
Kisspeptin 10mg is widely recognized among researchers for its potential applications in understanding hormone regulation and reproductive biology, making it an invaluable component for advancing studies in endocrinology and related fields.
| CAS No. | 374675-21-5 |
|---|---|
| Purity | ≥99% |
| Sequence | Tyr-Asn-Trp-Asn-Ser-Phe-Gly-Leu-Arg-Phe-NH2 |
| Molecular Formula | C63H83N17O14 |
| Molecular Weight | 4113.64 g/mol |
| Synthesis | Solid-phase synthesis |
| Solubility | Soluble in water or 1% acetic acid |
| Stability & Storage | Stable for up to 24 months at -20°C. After reconstitution, may be stored at 4°C for up to 4 weeks or at -20°C for up to 6 months. |
| Applications | Metabolic function research, obesity management, type 2 diabetes studies |
| Appearance | White lyophilized powder |
| Shipping Conditions | Shipped at ambient temperature; once received, store at -20°C |
| Regulatory/Compliance | Manufactured in a facility that adheres to cGMP guidelines |
| Safety Information | Refer to provided MSDS |
Consider these supplementary peptides for a comprehensive research approach.
For research teams evaluating where to buy Kisspeptin-10 for research, the key question is documentation, not product claims. Kisspeptin-10 is discussed in published literature as a KiSS1-derived decapeptide associated with KISS1R, also called GPR54, receptor research [1] [2]. This Pure Lab Peptides product-page guide keeps the discussion strictly for research use and focuses on compound identity, literature interpretation, COA review, analytical testing, labeling, and procurement documentation.
Researchers looking to buy Kisspeptin-10 for research should first review RUO labeling, the compound name, lot-specific certificate of analysis, peptide purity data, identity testing, molecular weight, and handling and storage documentation. Products discussed in this article are intended for laboratory research use only and are not intended for human or animal consumption. Published literature should be treated as research context, not product-use guidance.
Commercial research intent is different from consumer buying intent. A laboratory buyer is not evaluating a peptide for personal outcomes. The better question is whether the research material is documented clearly enough for technical review.
For Kisspeptin-10, that means reviewing peptide identity, COA availability, batch traceability, and literature context. PubChem lists Kisspeptin-10 with the formula C63H83N17O14 and a molecular weight near 1302.4 g/mol [1]. That type of identity information helps researchers compare the product listing against independent database records.
The first documentation layer should be the product label and batch-specific certificate of analysis. The next layer should be analytical testing details, such as HPLC purity and LC-MS identity support when available. HPLC is widely used in peptide analysis and purification, especially for separating peptide material and related impurities [4].
A research buyer should also check that the lot number, compound name, and testing date are consistent. FDA Q7 guidance emphasizes quality systems, laboratory controls, and documentation principles for materials represented by quality characteristics [6].
RUO labeling defines the product-page boundary. It keeps the focus on laboratory research, analytical review, and documentation, not consumer-facing claims. That is especially important for kisspeptin peptides because academic literature spans receptor biology, endocrine pathway research, and model-specific findings [7].
Kisspeptin-10 research use belongs in a documentation-first product-page framework. The page should help qualified professionals evaluate the material as a research peptide, not interpret it as a clinical, consumer, or wellness product.
Research use means the compound is discussed for laboratory research purposes only. For Kisspeptin-10, the relevant context includes compound identity, receptor gpr54 literature, peptide sequence, in vitro research models, and analytical testing.
Kisspeptin peptides are described as products of the KISS1 gene and ligands for the G protein-coupled receptor GPR54, also called KISS1R [7] [8]. This is receptor research context only.
A product page should frame Kisspeptin-10 as a laboratory material with supporting documentation. It should not frame the compound through therapeutic language, product effects, or product performance. Those phrases can drift into claim territory when separated from model-specific literature.
Documentation is more useful than promotional language. A strong research procurement review asks whether the peptide listing, COA, label, and lot details align. This approach helps researchers evaluate research peptides without turning academic findings into product positioning.
Kisspeptin-10 is generally discussed as a short kisspeptin peptide fragment. Official pharmacology resources list the peptide sequence as YNWNSFGLRF, with an amidated C-terminal phenylalanine [2].
Kisspeptin-10 is a decapeptide associated with the kisspeptin family. The broader kisspeptin family includes kisspeptin-54 and shorter fragments produced from KISS1-related peptide biology [3]. The compound is commonly discussed in receptor and signal transduction literature.
Kisspeptin is the broader family term. Kisspeptin-10, also known as KP-10 in some literature, refers to a shorter fragment that retains the conserved C-terminal region discussed in receptor research [3]. This distinction matters because product documentation should identify the exact compound.
KP-10 is discussed as a peptide fragment because shorter kisspeptin peptides share the C-terminal sequence region associated with KISS1R interaction [2] [3]. For product-page research review, that makes sequence documentation and molecular weight especially important.
Molecular identity is the foundation of Kisspeptin-10 peptide review. A research material should be evaluated against its compound name, formula, molecular weight, and sequence records.
Molecular weight helps researchers compare product documentation with independent compound references. PubChem lists Kisspeptin-10 at approximately 1302.4 g/mol [1]. A COA or product record should not conflict with the expected molecular identity.
The peptide sequence YNWNSFGLRF is listed for kisspeptin-10 by the IUPHAR Guide to Pharmacology [2]. Sequence review is useful because closely related kisspeptins and species-specific fragments can differ in structure.
The C-terminal region is central in kisspeptin fragment discussions. IUPHAR notes that the C-terminal phenylalanine is amidated for kisspeptin-10 [2]. This is a compound-identity detail, not a product claim.
Kisspeptin-10 research often appears in the context of KISS1R, also called GPR54. This receptor context helps researchers understand why the compound appears in neuropeptide and cell signaling literature.
GPR54, also known as KISS1R, is a G protein-coupled receptor associated with kisspeptin ligand research [8]. Published reviews describe kisspeptins as peptide products of the KiSS-1 gene and natural ligands of GPR54 [7].
The KiSS1 gene and kisspeptin receptor context are closely linked in the literature. Kotani and colleagues identified peptides encoded by the metastasis suppressor gene KiSS-1 as ligands of the previously orphan receptor GPR54 [9]. This is useful background for understanding receptor-pathway research.
Receptor pathway language can become misleading if it is written as a product claim. A safe product page should say that literature examines receptor interaction and signaling pathways. It should not say or imply that a product produces outcomes outside laboratory research.
Cell signaling gives Kisspeptin-10 its research-lane relevance. The literature discusses kisspeptin and GPR54 in signal pathways, receptor biology, and model-specific experimental systems.
Published literature frames kisspeptin-GPR54 signaling as a receptor-ligand system. Reviews describe the system in relation to GnRH neuron signaling and endocrine pathway research [7] [10]. Product-page copy should present this as literature context only.
Signal transduction refers to how receptor interaction is studied in model systems. In kisspeptin research, this may involve receptor activation, pathway mapping, and downstream signaling markers. These are research-model concepts, not claims about RUO material performance.
Pathway relevance means a compound appears in published research about a pathway. It does not mean the product is positioned for clinical-use language, therapeutic language, or consumer outcome claims. RUO content should keep that line clear.
In vitro research can help characterize receptor and signaling questions under controlled laboratory settings. It cannot be used to make product-use claims.
In vitro models can clarify receptor interaction, peptide response markers, and assay-specific pathway activity. Kotani and colleagues’ work helped define KiSS-1-derived peptide receptor biology in experimental contexts [9]. Such findings remain model-specific.
Laboratory settings define the limits of interpretation. A cell model, receptor assay, or biochemical experiment can show what happened under specific study conditions. It cannot automatically be generalized into product positioning.
Model design affects what a study can show. A study may involve a particular cell line, receptor system, analytical method, or measurement window. Product pages should avoid converting those details into broad claims.
The kisspeptin literature is broad, so source quality matters. Researchers should separate original mechanistic studies, database records, reviews, analytical references, and vendor claims.
A safe source quality filter starts with official databases, peer-reviewed studies, and review articles. PubChem and IUPHAR support compound identity review [1] [2]. PubMed-indexed reviews support receptor and pathway context [7] [10].
Literature can establish how a compound has been studied, what models were used, and which receptors or pathways were examined. It cannot establish claims for a research-use-only product page. Some published literature outside the scope of RUO product use has examined this compound class in human study settings. That literature should not be interpreted as a use claim for research-use-only materials.
Named studies belong in literature context because they identify where a claim came from. For example, Tena-Sempere reviewed experimental evidence relating kisspeptins and GPR54 to GnRH regulation [7]. The safe interpretation is that this supports pathway awareness, not product positioning.
A research article can discuss what literature examines without claiming what a product does. That separation is essential for RUO peptide product pages.
Study findings are tied to model systems, methods, and limitations. A result in receptor or pathway literature does not become a claim for a listed research material. Phrases related to product effects require careful framing because they can become product claims if removed from model-specific literature context.
Claim boundaries help keep product pages focused on documentation. For Kisspeptin-10, safe product-page content emphasizes molecular identity, certificate of analysis review, HPLC, LC-MS, lot traceability, and RUO labeling.
Product documentation should emphasize what can be checked. That includes product name, lot number, purity method, identity method, COA date, labeling consistency, and handling and storage conditions. This is the practical core of research procurement.
A certificate of analysis is a key product-page document. It should support batch-specific review rather than serve as a marketing claim.
A COA should identify the tested material, lot or batch, testing method, result, and date. ICH Q7 guidance notes that quality documentation and laboratory controls are part of a broader quality system for materials with stated quality characteristics [11]. Research buyers should review whether the COA matches the product listing.
COA data supports procurement by creating a record for review. It can show whether a batch was tested for purity and whether identity information is available. FDA Q7 Q&A guidance also notes that a supplier’s COA may not necessarily align with the user’s specifications, which supports independent review by the receiving organization [12].
Batch-specific documentation matters because peptide materials can vary by lot. A COA should be tied to the batch being evaluated. A generic document is less useful than a lot-specific record with clear testing details.
Analytical testing helps researchers evaluate whether documentation supports the product listing. It should not be framed as proof of product performance.
High-performance liquid chromatography is used in peptide purification and analysis, including reversed-phase, ion-exchange, and size-exclusion modes [4]. In product documentation, HPLC can help review peptide purity by showing chromatographic separation and peak reporting.
LC-MS can support peptide identity review because mass spectrometry provides mass-related information that helps characterize peptides. LC-HRMS methods have been used for qualitative and quantitative identification and characterization of peptide-related materials and impurities [5].
Chromatogram review adds method-level transparency. It can help researchers see peak patterns, retention information, and reported purity. A chromatogram should be read alongside identity testing and batch documentation, not in isolation.
| Research Area | What Literature Examines | Evidence Type | RUO Interpretation |
|---|---|---|---|
| Compound identity | Formula, molecular weight, and database identity for Kisspeptin-10 [1] | Official database | Supports documentation review only |
| Receptor context | Kisspeptins as ligands for GPR54/KISS1R [7] | Peer-reviewed review | Supports pathway context only |
| Peptide sequence | YNWNSFGLRF and C-terminal amidation [2] | Official pharmacology database | Supports identity review |
| Purity review | HPLC methods for peptide analysis [4] | Analytical literature | Supports documentation review |
| Identity testing | LC-MS characterization of peptide materials [5] | Analytical literature | Supports identity-focused review |
Lot traceability helps connect the product listing to the specific research material. It also helps technical teams organize procurement records.
Lot numbers matter because they connect labeling, COA, and batch records. Without lot traceability, a COA cannot be confidently matched to the product being reviewed. ICH Q7 emphasizes documentation systems, batch records, and laboratory controls as part of quality management [11].
Research buyers should compare documentation quality, not consumer claims. Useful comparison points include COA availability, test method disclosure, lot matching, identity data, storage notes, and RUO labeling.
Documentation consistency reduces ambiguity. The compound name, molecular weight, lot number, and label should tell the same story. When documents conflict, researchers should resolve the discrepancy before procurement decisions are finalized.
Handling and storage documentation belongs in research records. It should describe laboratory material stewardship without drifting into product-use instructions.
Handling and storage records should clarify storage conditions, label requirements, document retention, and batch identification. ICH Q7 includes guidance on storage, distribution, packaging, labeling, and laboratory controls for quality systems [11].
Lyophilized material documentation matters because freeze drying is a common way to stabilize peptide materials for laboratory distribution. Documentation should distinguish the physical form, label, and storage expectations without presenting any product-use instructions.
Labeling consistency helps connect the vial label, product record, and COA. For Kisspeptin-10, the label should not conflict with the expected compound identity or lot documentation. Consistency is a procurement quality check.
Misunderstandings often begin when search language is treated as product-page language. RUO pages should prevent that drift.
A 10mg reference is a catalog or listing specification. It should not be treated as an experimental recommendation, product-use amount, or research instruction. The canonical product-page entity remains Kisspeptin-10.
Research context discusses what literature examines, what documentation shows, and what analytical testing can support. Product-use language implies directions, outcomes, or intended applications beyond RUO positioning. Those categories must remain separate.
Compound research is not consumer guidance. A receptor pathway, molecular target, or literature finding does not support personal-use positioning. RUO product pages should keep the focus on qualified laboratory research and documentation review.
A procurement checklist helps research teams evaluate Kisspeptin-10 documentation without relying on claims.
A strong review separates three layers. The COA supports batch-level analytical review. The label supports product identification and RUO positioning. Published literature supports scientific context, but it does not define the intended purpose of the listed research material.
Lab-test verification protocol:
Pure Lab Peptides supplies compounds for laboratory research use only. Products are not intended for human or animal consumption, diagnostic use, therapeutic use, clinical use, veterinary use, or as food, drugs, cosmetics, dietary supplements, or household products. Researchers are responsible for ensuring lawful, appropriate handling and use in accordance with applicable regulations and institutional guidelines.
Review the product-page documentation, COA details, and RUO labeling before evaluating this compound for laboratory research.
Kisspeptin-10 is described in research literature as a decapeptide and peptide fragment within the broader kisspeptins family. In RUO product-page context, it should be evaluated through compound identity, sequence documentation, receptor context, and research documentation rather than consumer-facing product claims.
Kisspeptin-10 is discussed as a short peptide fragment associated with the Kiss-1 research pathway. Product-page research discussion should focus on how the compound is identified, how documentation describes the material, and whether supplier records support identity review, not on applied or personal-use interpretations.
Kisspeptin-10 is commonly discussed in relation to kiss1r and receptor-pathway literature. For RUO pages, that signaling and receptor interaction context should remain tied to published research models, compound characterization, and documentation review rather than product claims.
Researchers should consider RUO labeling, batch-specific documentation, COA availability, identity review, supplier records, and consistency across product documentation. The phrase buy Kisspeptin-10 for research should be interpreted as laboratory procurement intent, not consumer or clinical-use intent.
Research models are important because they define what a study can and cannot show. A receptor assay, in-vitro model, or pathway-focused experiment provides controlled research context, but those findings should not be translated into product claims or broader application statements.
Kisspeptin-10 product pages stay research-use-only by focusing on qualified professionals, compound identity, COA review, analytical testing, lot traceability, and documentation. Boundary-sensitive phrases should be kept separate from product positioning and handled only as examples of language that can drift away from RUO context.
The following authors are recognized for published research that helped shape the scientific context discussed in this article.
Author profile: ORCID
Manuel Tena-Sempere is a research author whose publications are relevant to kisspeptin, GPR54, and neuropeptide pathway literature. His work helps provide background for interpreting Kisspeptin-10 in a receptor-pathway research setting, especially where product-page content must separate published literature from research-use-only product positioning. His publications are useful for understanding how kisspeptins have been discussed across peptide signaling, Kiss-1, and GPR54 research contexts.
Selected publications:
Author profile: University of Cambridge Profile
William H. Colledge is a published researcher whose work is relevant to Kiss1, GPR54, and GnRH-neuron signaling models. His publications help support the broader scientific background for receptor-focused Kisspeptin-10 research pages. In this context, his work is most useful for understanding how kisspeptin receptor literature is organized, how model-specific findings should be interpreted, and why pathway-focused research language should remain separate from product claims.
Selected publications:
This research disclaimer clarifies how this page handles published literature and search language around Kisspeptin-10. In neuropeptide and receptor research content, terms such as metastasis suppressor, LH, stimulate, secretion, biological activity, GnRH release, and neuroendocrine can drift into consumer-facing, clinical-use, therapeutic-use, wellness, or product-claim language when framed outside model-specific research context.
Here, those phrases are handled only as research-language examples, not product uses, outcomes, instructions, or recommendations. The focus remains on Kisspeptin-10 identity, COA review, analytical testing, peptide purity, lot traceability, research-use-only labeling, product documentation, and published literature boundaries, including careful separation of terms such as melanoma, luteinizing hormone, tumor metastasis, hormonal, follicle-stimulating hormone, neuroprotective, and cholinergic from product positioning.
Our team is ready to assist you with any inquiries regarding our catalogue of peptides and their applications.
Discount Applied Successfully!
Your savings have been added to the cart.
There are no reviews yet.